Nanoparticles for sustained release of active agents for the treatment of pulmonary hypertension
Pulmonary hypertension is a serious, lifethreatening
disorder which substantially restricts physical capacities and results in a severely reduced life expectancy with an average survival time of only 2.8 years after diagnosis if the disease is not treated.<br> The new nanoparticles now allow a controlled release of inhalable active agents for pulmonary hypertension over a long period of time, thus leading to a prolongation of pharmacological effects and a considerably improved quality of patients' life.
Further Information: PDF
TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12
Contact
Dr. Peter Stumpf
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Bringing bio-inspired robots to life
Nebraska researcher Eric Markvicka gets NSF CAREER Award to pursue manufacture of novel materials for soft robotics and stretchable electronics. Engineers are increasingly eager to develop robots that mimic the…
Bella moths use poison to attract mates
Scientists are closer to finding out how. Pyrrolizidine alkaloids are as bitter and toxic as they are hard to pronounce. They’re produced by several different types of plants and are…
AI tool creates ‘synthetic’ images of cells
…for enhanced microscopy analysis. Observing individual cells through microscopes can reveal a range of important cell biological phenomena that frequently play a role in human diseases, but the process of…
